Sarepta Therapeutics, Inc.'s SEC filings document an operating biopharmaceutical company with common stock listed on the Nasdaq Global Select Market under SRPT. Form 8-K reports furnish quarterly and annual financial results, product revenue disclosures for ELEVIDYS and PMO therapies, and clinical or regulatory updates for Duchenne muscular dystrophy treatments and siRNA pipeline programs.
Other filings cover proxy governance, executive compensation, equity-award plans and leadership-transition disclosures. Material-event reports also describe capital-structure actions, including exchange agreements for convertible senior notes, issuance of new convertible notes, common stock consideration and related indenture terms.
Sarepta Therapeutics reported a sharp swing to profitability in the first quarter of 2026 while advancing its Duchenne and RNA pipelines. Total revenues were $730.8 million, down slightly from $744.9 million a year ago, as lower ELEVIDYS product volume from an ambulatory‑only label was offset by higher collaboration and contract manufacturing revenues, including $365.0 million tied to Roche’s declined option and a $40.0 million ELEVIDYS launch milestone in Japan.
GAAP operating income reached $358.4 million versus a loss of $300.4 million, and GAAP net income was $331.0 million compared with a $447.5 million loss, reflecting reduced R&D and SG&A after a 2025 pipeline reprioritization and the absence of prior Arrowhead upfront charges. Non‑GAAP operating income was $397.7 million and non‑GAAP net income was $385.4 million.
The company ended March 31, 2026 with $748.3 million in cash, cash equivalents, restricted cash and investments, down from $953.8 million at year‑end, and reaffirmed 2026 guidance for total net product revenues of $1.2–$1.4 billion and combined non‑GAAP R&D and SG&A expenses of $800.0–$900.0 million. Sarepta highlighted early Phase 1/2 siRNA data in FSHD1 and DM1, progress in ENDEAVOR Cohort 8 using sirolimus pretreatment for ELEVIDYS in non‑ambulatory Duchenne patients, and sNDAs seeking traditional approvals for AMONDYS 45 and VYONDYS 53.
Sarepta Therapeutics Inc is reported as having 5,369,116 shares beneficially owned by Vanguard Capital Management, representing 5.11% of the common stock. The filing states Vanguard has sole voting power for 790,881 shares and sole dispositive power for 5,369,116 shares. The disclosure attributes ownership across Vanguard affiliates as described in the filing.
Sarepta Therapeutics: Vanguard Portfolio Management reports ownership of 6,751,168 shares of Common Stock, representing 6.43% of the class. The filing states Vanguard has sole dispositive power over 6,751,168 shares and sole voting power over 110,476 shares. The statement is signed by Ashley Grim on 04/29/2026.
Sarepta Therapeutics is asking stockholders to vote at its June 4, 2026 virtual annual meeting on five key items. Investors are asked to elect five Class I directors to serve until 2028, approve on an advisory basis 2025 executive pay, and ratify KPMG LLP as auditor for 2026.
The company also seeks approval of a new 2026 Equity Incentive Plan covering 6,740,000 shares and a 2026 Employee Stock Purchase Plan covering 1,500,000 shares. The proxy links these equity programs to retaining and motivating key talent during a planned CEO transition, as the current chief executive intends to retire by the end of 2026 or upon appointment of a successor.
Sarepta Therapeutics Inc ownership filing shows that The Vanguard Group reports 0 shares beneficially owned of Common Stock, representing 0% of the class. The filing notes an internal realignment effective January 12, 2026, under SEC Release No. 34-39538, causing certain Vanguard subsidiaries to report separately.
Sarepta Therapeutics, Inc. Chief Operating Officer Ian Michael Estepan reported a routine tax-related share disposition. On March 11, he had 1,097 shares of common stock withheld by the company at $17.03 per share to cover tax obligations tied to vesting of restricted stock units granted on March 10, 2025. After this withholding, he directly held 201,983 shares of Sarepta common stock, indicating he retains a substantial equity position in the company.
Sarepta Therapeutics, Inc. Chief Financial Officer Ryan Ho-Yan Wong reported a small share disposition tied to tax withholding, not an open-market trade. On March 11, 256 shares of common stock were withheld by the company at $17.03 per share to cover taxes on restricted stock units that vested from a grant dated March 10, 2025.
After this tax-withholding event, Wong directly holds 135,064 shares of Sarepta common stock. Because the shares were withheld to satisfy tax obligations rather than sold in the market, this filing reflects a routine compensation-related adjustment rather than a discretionary purchase or sale.
Sarepta Therapeutics, Inc. executive Louise Rodino-Klapac, President of R&D and Tech Ops, had 948 shares of common stock withheld on March 11, 2026 to cover tax obligations linked to restricted stock units that vested from a grant dated March 10, 2025. The shares were valued at $17.03 each for this tax-withholding calculation. After this transaction, she directly holds 225,323 shares of common stock, indicating this was a small, routine adjustment related to equity compensation rather than an open-market trade.